Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21273875 | 1.00 | ARG2 (1.00) | ARG2ARG1 | |
| SCHEMBL21273893 | 1.00 | ARG2 (1.00) | ARG2ARG1 | |
| SCHEMBL21285570 | 1.00 | ARG2 (1.00) | ARG2ARG1 | |
| SCHEMBL21285623 | 1.00 | ARG2 (1.00) | ARG2ARG1 | |
| SCHEMBL21285626 | 0.89 | ARG2 (0.80) | ARG2ARG1 | |
| SCHEMBL24296971 | 0.86 | ARG2 (1.00) | ARG2ARG1 | |
| SCHEMBL22322637 | 0.86 | ARG2 (1.00) | ARG2ARG1 | |
| SCHEMBL22322862 | 0.86 | ARG2 (1.00) | ARG2ARG1 | |
| SCHEMBL22322617 | 0.86 | ARG2 (1.00) | ARG2ARG1 | |
| SCHEMBL22338288 | 0.86 | ARG2 (1.00) | ARG2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313578-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| US-12195485-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2025-01-14 | — | — | US | disclosed |
| US-11912727-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2024-02-27 | — | — | US | disclosed |
| US-11912727-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2024-02-27 | — | — | US | disclosed |
| CN-117180290-A | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230365599-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2023-11-16 | — | — | US | disclosed |
| US-20230365599-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2023-11-16 | — | — | US | disclosed |
| US-20230365599-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2023-11-16 | — | — | US | disclosed |
| CN-111712302-B | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230122859-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11420984-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2022-08-23 | — | — | US | disclosed |
| US-11420984-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2022-08-23 | — | — | US | disclosed |
| US-20210002305-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA UK LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| WO-2019159120-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.